Skip to search formSkip to main contentSkip to account menu
Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of…
TLDR
Use of metabolic rates from cDNA-expressed CYPs containing nonphysiologic concentrations of electron-transfer proteins in conjunction with hepatic CYP contents may lead to incorrect predictions of liver microsomal rates and relative contributions of individual isoforms.
View on PubMed
Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice
View on Wiley
Effect of Age, Gender, and Obesity on Midazolam Kinetics
TLDR
Midazolam elimination half‐life (t1/2) after iv dosage was significantly prolonged in elderly (aged 60‐74 yr) versus young (24‐33 yr) males and in obese subjects (8.4 vs. 2.7, P < 0.001) and Vd was greater in the obese subjects even after correction for total weight, indicating disproportionate distribution of midAZolam into adipose weight.
View on Wolters Kluwer
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.
TLDR
S-CT, biotransformed by three CYP isoforms in parallel, is unlikely to be affected by drug interactions or genetic polymorphisms and are also unlikely to cause clinically important drug interactions via CYP inhibition.
View on PubMed
O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants
View on Springer
Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents
TLDR
Results are consistent with results of other in vitro studies and of clinical studies, indicating that fluoxetine, largely via its metabolite norfluoxettine, may impair clearance of P450‐3A substrates.
View on Wiley
Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors
TLDR
In vitro microsomal model provides relevant predictive data on probable drug interactions with NNRTIs when the mechanism is inhibition of CYP‐mediated drug biotransformation, however, the model does not incorporate interactions attributable to enzyme induction.
View on Wiley
Inhibition of human cytochromes P450 by components of Ginkgo biloba
TLDR
The principal components of Ginkgo biloba preparations in clinical use do not significantly inhibit these human CYPs in‐vitro, however, flavonol aglycones, the biflavonol amentoflavone and several other non‐glycosidic constituents are significant in‐Vitro inhibitors of CYP.
View on Wiley
Population Pharmacokinetics of Methylphenidate in Children with Attention‐Deficit Hyperactivity Disorder
TLDR
The relatively noninvasive approach used in this study allows the assessment of pharmacokinetic properties of medications under conditions of appropriate clinical use in special populations such as children, adolescents, and the elderly.
View on Wiley
Drug interactions with newer antidepressants: role of human cytochromes P450.
TLDR
This review evaluates the clinical implications of the metabolic profiles of the newer antidepressants, the relative activities of various new antidepressants as inhibitors of human cytochrome P450, and the various in vivo and in vitro methodologies that can be used for identification and quantification of drug interactions.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License